Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
about
How to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemia: Integrating genomics into therapyA robust in vivo model for B cell precursor acute lymphoblastic leukemiaEvolved Cellular Mechanisms to Respond to Genotoxic Insults: Implications for Radiation-Induced Hematologic MalignanciesChemotherapy drug shortages in pediatric oncology: a consensus statementDexamethasone Chemotherapy Does Not Disrupt Orexin SignalingIntegration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray studyManagement of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's OnMitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.Improving the outcome for children with cancer: Development of targeted new agents.Evaluation and Management of Chronic PancytopeniaMinimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.A 50-year journey to cure childhood acute lymphoblastic leukemiaHow Well Do All Patient Refined-Diagnosis-Related Groups Explain Costs of Pediatric Cancer Chemotherapy Admissions in the United States?Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia.Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Ph-like acute lymphoblastic leukemia.When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.Pediatric haematopoiesis and related malignancies.Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases.HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia.STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia & lymphoma (TACL) consortium supportive care committee.A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).Quality of life Evaluation in patients receiving Steroids (the QuESt tool): initial development in children and young people with acute lymphoblastic leukaemia.Study of Posterior Reversible Encephalopathy Syndrome in Children With Acute Lymphoblastic Leukemia After Induction Chemotherapy.Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study.Association of ARID5B Genetic Variants with Risk of Childhood B Cell Precursor Acute Lymphoblastic Leukaemia in LatviaCD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients.Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.
P2860
Q27026952-9A136EAB-514A-47EA-AA23-36A0EC0E72DAQ28080463-41AE7D78-52AF-4F26-93BC-74D67017521CQ28085325-6994A6D1-9E05-4521-AC92-3B84F2EB320DQ28085534-69A0147C-BFF7-4575-95C5-35B8CB14487FQ28307153-7CED29B2-B591-49C2-A5BC-0197FD982F07Q28555144-C136A67D-276C-4313-BEC4-E0F2E1BA35E3Q30842603-0DBA10A4-3BD9-4D82-B5C2-B120824006CEQ33762835-8CBDF306-1892-4C9A-B265-F20C689D7B9CQ34079996-2257F036-2A48-461F-BD99-FF582C9BEDFAQ35039727-9F428B05-E0EE-4CA0-AC86-178C4093B800Q35049636-5997C7FF-1F7F-45DD-AF7C-E377F3D888B2Q35904943-F62DEAA4-36AF-4879-BC50-AC5353742E27Q36238795-FB63BDD3-2AA4-4F69-85DE-D0B4D9CA5BF9Q36608344-29C7CE7A-A7C2-4F88-B802-D76C49957C7BQ36731638-7AB0606B-29F6-40B4-8899-894E6B9EF93DQ36762608-955C80FE-52C2-419C-885E-E41D8210E477Q37166753-BD1276D0-0541-47F2-9666-50DD9A3667EBQ37240926-7D8D20BC-DB0D-4EFD-8BEB-C7D85A98158AQ37327945-84DF7C39-37F4-433E-9E39-3438FF8F6627Q37716294-EA138919-81D5-495F-8F80-09C6E35BD570Q38289038-20035F11-E75C-4DCF-A193-621DFD313747Q38821455-3C5E9D5F-3125-4ABB-9B61-D4C25DFF17B1Q38878469-FDD801A0-0763-4805-B201-085DE4431608Q38933372-F0F14A3E-863C-460E-9035-6742180378C7Q39027852-F2C25075-8628-42E1-BA5B-B3971629583EQ39420711-7A30DDF3-FD83-4E78-A42E-AD6521D16429Q39425967-B3ADEF94-3B0F-4D72-AE11-BF26B8212B6CQ39571116-35A5BD98-C976-46A7-9C2A-7549172FC168Q41179706-3BCE06DB-2E74-4FFC-BE44-6320F9864DD2Q42771346-B19CAACE-9D0B-484A-AD2C-7A8B1B555FD5Q43109007-104FC491-13B4-4E96-B0CE-EB4478FCDBBDQ45072276-686A1E5F-6DD3-479A-9273-EE8BA495CF7CQ46516037-19F52695-F5DA-4805-A7B1-B44724EE9030Q47614484-C64AE27F-A113-42A3-AFC8-F9B158B752A8Q47874296-2D90CBCA-A4C2-48CD-AFBA-08D4FE7CA831Q48135658-984AAFAB-F8F6-4816-9EF5-5B30C08EF2F8Q48262886-5BB4C88C-8E14-4210-8026-232CAC91D9D0Q49648730-E8150186-1CCD-477E-8DB8-B838A61BE472Q51041845-260D8B93-4045-4FF5-999A-A22223EE2A40Q52870427-5718CDA9-FF8B-4291-94EF-3B1381C47A62
P2860
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@ast
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@en
type
label
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@ast
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@en
prefLabel
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@ast
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@en
P2093
P2860
P356
P1476
Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.
@en
P2093
COG Acute Lymphoblastic Leukemia Committee
Elizabeth A Raetz
James A Whitlock
Meenakshi Devidas
Mignon L Loh
Naomi J Winick
William L Carroll
P2860
P304
P356
10.1002/PBC.24420
P577
2012-12-19T00:00:00Z